Tang Jang Wang

6423503, Jul 23, 2002

Apr 30, 1999

09/303339

Stephen D. Mikolajczyk - San Diego CA
Tang Jang Wang - Poway CA
Harry G. Rittenhouse - Del Mar CA
Robert L. Wolfert - San Diego CA
Kevin Slawin - Houston TX

Hybritech Incorporated - Fullerton CA
Baylor College of Medicine - Houston TX

G01N 33574

435 723, 435 4, 435 71, 435 72, 435960, 435975, 436 63, 436 64, 436811, 436813, 424 91

A method of distinguishing prostate cancer from benign prostatic hyperplasia (BPH) is provided. The mathematical combination or ratio of proPSA and BPSA serum or tissue markers may be used for distinguishing benign prostatic hyperplasia (BPH) from prostate cancer. It is the discovery of the present invention that BPSA is preferentially elevated in transition zone prostate tissue whereas pPSA is elevated in the peripheral zone of prostate tissue. A kit for aiding in distinguishing BPH from prostate cancer is also provided.

6482599, Nov 19, 2002

Apr 30, 1999

09/303208

Stephen D. Mikolajczyk - San Diego CA
Tang Jang Wang - Poway CA
Harry G. Rittenhouse - Del Mar CA
Robert L. Wolfert - San Diego CA
Kevin Slawin - Houston TX

Hybritech Incorporated - San Diego CA

G01N 33574

435 723, 435 4, 435 71, 435 721, 435 72, 435 792, 435 701, 435 7021, 435 41, 436 63, 436 64, 436174, 530300, 530350, 530386, 5303871, 5303877, 5303879, 5303881, 53038815

A substantially pure and isolated novel form of prostate specific antigen (PSA) is provided. The novel form of PSA of the present invention comprises at least one clip at Lys 182 of the amino acid sequence of a mature form of PSA. Preferably, the novel form of PSA additionally comprises one or more clips at a location selected from a group consisting of Ile 1, Lys 145, and Lys 146. More preferably, the form of PSA contains at least two clips at Lys 145 and Lys 182 of the amino acid sequence of a mature form of PSA. The novel forms of PSA exist at an elevated level in patients suspected of having benign prostatic hyperplasia (BPH) and therefore may be used as a serum mark or an immunohistological marker to help distinguish BPH from prostate cancer. Antibodies recognizing the novel forms of PSA and immunoassays that detect and determine the novel forms of PSA of the present invention in a sample are also provided. Further provided are a kit and a method for detecting the novel forms of PSA for aiding in the differentiation of prostate cancer from BPH.

6764825, Jul 20, 2004

Oct 13, 2000

09/687017

Tang J. Wang - Poway CA, 92064

G01N 3353

435 71, 435 74, 435 75, 435 76, 435 79, 435 792, 435 793, 435 794, 435975, 436514, 436518, 436524, 436810, 436825

An immunoassay device and assay to detect an antigen, such as PSA, in a biological sample. The device comprises a solid support having multiple reaction zones containing capture antibodies directed to the antigen. Exposure of a test sample to a mixture of incubation antibodies with known and different concentrations prior to exposure to the capture antibodies in the reaction zones facilitates determination of a range of concentrations of the antigen.

7300761, Nov 27, 2007

May 20, 2004

10/851253

Tang J. Wang - Poway CA, US

G01N 33/533

435 71, 435 74, 435 75, 435 76, 435 79, 435 792, 435 793, 435 794, 435975, 436514, 436518, 436524, 436810, 436825

An immunoassay device and assay to detect an antigen, such as PSA, in a biological sample. The device comprises a solid support having multiple reaction zones containing capture antibodies directed to the antigen. Exposure of a test sample to a mixture of incubation antibodies with known and different concentrations prior to exposure to the capture antibodies in the reaction zones facilitates determination of a range of concentrations of the antigen.

7659073, Feb 9, 2010

Feb 23, 2001

09/792534

Stephen D. Mikolajczyk - San Diego CA, US
Harry G. Rittenhouse - Del Mar CA, US
Tang Jang Wang - Poway CA, US
Robert L. Wolfert - Palo Alto CA, US

Hybritech Incorporated - San Diego CA

G01N 33/53

435 71, 530300, 530350

Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer.

20030119033, Jun 26, 2003

Sep 24, 2002

10/252862

Stephen Mikolajczyk - San Diego CA, US
Tang Wang - Poway CA, US
Harry Rittenhouse - Del Mar CA, US
Robert Wolfert - San Diego CA, US
Kevin Slawin - Houston TX, US

Hybritech Incorporated and Baylor College of Medicine

C12Q001/68
G01N033/574
C07H021/04
C12N009/00
C12P021/02
C12N005/06
C07K016/30

435/006000, 435/007230, 435/069300, 435/183000, 435/320100, 435/325000, 536/023200, 530/388260

A substantially pure and isolated novel form of prostate specific antigen (PSA) is provided. The novel form of PSA of the present invention comprises at least one clip at Lys 182 of the amino acid sequence of a mature form of PSA. Preferably, the novel form of PSA additionally comprises one or more clips at a location selected from a group consisting of Ile 1, Lys 145, and Lys 146. More preferably, the form of PSA contains at least two clips at Lys 145 and Lys 182 of the amino acid sequence of a mature form of PSA. The novel forms of PSA exist at an elevated level in patients suspected of having benign prostatic hyperplasia (BPH) and therefore may be used as a serum mark or an immunohistological marker to help distinguish BPH from prostate cancer. Antibodies recognizing the novel forms of PSA and immunoassays that detect and determine the novel forms of PSA of the present invention in a sample are also provided. Further provided are a kit and a method for detecting the novel forms of PSA for aiding in the differentiation of prostate cancer from BPH.

20100151501, Jun 17, 2010

Dec 7, 2009

12/632640

Stephen D. MIKOLAJCZYK - San Diego CA, US
Harry G. Rittenhouse - Del Mar CA, US
Tang Jang Wang - Poway CA, US
Robert L. Wolfert - Palo Alto CA, US

G01N 33/574

435 723

Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer.

58561820, Jan 5, 1999

Nov 18, 1996

8/749525

Kristine Kuus-Reichel - San Diego CA
Harry Jay Linton - Encinitas CA
Janice K. Payne - San Diego CA
Tang J. Wang - Poway CA

Beckman Coulter, Inc. - Fullerton CA

C12N 506
C12N 516
G01N 33574
C07K 1600

435330

Monoclonal antibodies have been developed which specifically bind the PSA-ACT complex without significant cross-reactivity with PSA, ACT or CG-ACT. The antibodies were generated using a unique immunogen comprising a PSA-ACT complex having bound to monoclonal antibodies against PSA and monoclonal antibodies against ACT. It is theorized that the antibodies against PSA and ACT block immunodominant sites on the PSA-ACT complex. The antibodies generated against the unique immunogen specifically bind the PSA-ACT complex, but have no significant cross-reactivity with either PSA or ACT. The monoclonal antibodies of the present invention can be used in immunoassays to specifically detect PSA-ACT in a sample.